基于小胶质细胞功能障碍的阿尔茨海默病药物研发

发布时间：2018-06-09 16:14

本文选题：神经元 + 小胶质细胞　；参考：《药学学报》2017年11期

【摘要】：阿尔茨海默病(Alzheimer’s disease,AD)俗称老年痴呆,是严重威胁全球中老年人健康的神经退行性疾病。由于发病机制尚不明确,发病进程不可逆转,造成了AD难防难治。AD的主要症状是记忆、认知力的降低,源于神经元受损,但是基于神经元的AD新药研发近年来频遭失败,急需探索新的治疗路径。小胶质细胞作为中枢神经系统的最重要的免疫细胞,对神经元和大脑的功能维护起着重要的作用,小胶质细胞的过度活化导致的神经炎症反应也是AD的重要病理特征,参与到AD发病的各个环节,因此抑制小胶质细胞的过度活化,抑制神经炎症有望阻止AD的恶化进程。本文主要通过小胶质细胞与神经元之间的相互关联来论述靶向神经胶质细胞治疗AD的可能性,并分析了小分子药物的研究现状和神经炎症抑制剂用于AD治疗的重要意义。
[Abstract]:Alzheimer's disease (AD), commonly known as Alzheimer's disease, is a neurodegenerative disease that threatens the health of middle-aged and elderly people worldwide. Because the pathogenesis of AD is not clear and the process of AD is irreversible, the main symptom of AD is memory and cognitive decline, which originates from the damage of neurons. However, the research and development of new AD drugs based on neurons has been frequently failed in recent years. There is an urgent need to explore new therapeutic pathways. As the most important immune cells in the central nervous system, microglia play an important role in maintaining the function of neurons and brain. The neuroinflammatory response caused by excessive activation of microglia is also an important pathological feature of AD. Therefore, inhibiting the excessive activation of microglia and inhibiting neuroinflammation may prevent the progression of AD. In this paper, the possibility of targeted glial cell therapy for AD was discussed through the correlation between microglia and neurons, and the research status of small molecular drugs and the significance of neuroinflammatory inhibitors in AD therapy were analyzed.
【作者单位】：广州医科大学药学院;中国科学院广州生物医药与健康研究院;
【基金】：广东省自然科学基金资助项目(10251066302000000) 广东省重大科技专项资助项目(2012A080201013) 广州医科大学高水平大学建设项目
【分类号】：R91

【相似文献】